



Adult Respiratory Syncytial Virus (RSV) Session

Camille Kotton, MD

Chair, Adult RSV Work Group

Advisory Committee on Immunization Practices (ACIP)

October 20, 2022

Adult RSV Work Group Membership

ACIP Voting Members

Camille Kotton (chair)

Keipp Talbot

Sarah Long

Ex Officio Members

Rachel Zhang (FDA)

Judy Beeler (FDA)

Nicholas Geagan (FDA)

Sonnie Kim (NIH/NIAID)

Jeffrey Kelman (CMS)

Valerie Marshal (OIDP)

CDC Lead

Michael Melgar

Consultants

Robert Atmar (Baylor College of Medicine)

Angela Branche (University of Rochester)

Helen Chu (University of Washington)

Marie Griffin (Vanderbilt University Medical Center)

Cynthia Lucero-Obusan (Veterans Health Administration)

Tracy Ruckwardt (NIH/NIAID)

Liaisons

Kenneth Schmader (AGS)

Katherine Williams (APTR)

Shmuel Shoham (ACP)

Ruth Lynfield (NFID)

Gretchen LaSalle (AAFP)

Jennifer Heath (AIM)

April Killikelly (NACI, PHAC)

Winnie Su (NACI, PHAC)

Michael Hogue (APhA)

CDC Contributors

Coronavirus and Other Respiratory Viruses Division (proposed)

Fiona Havers

Tamara Pilishvili

Meredith McMorrow

Diya Surie

Lauren Roper

Mila Prill

Natalie Thornburg

Aron Hall

Jefferson Jones

Katherine Fleming-Dutra

Ismael Ortega-Sanchez

Immunization Safety Office

Anne Hause

David Shay

Christine Olson

Immunization Services Division

Neil Murthy

Patricia Wodi

Debra Blog

Andrew Leidner

Jamison Pike

Recap of RSV session, February 2023

- Introduction to the Adult RSV work group
- Orientation to the multiple vaccine products in development to prevent RSV disease in adults
- Overview of RSV virology and immunology
- Introduction to the seasonality and burden of RSV disease in the United States

Recent Work Group Discussion

- Selection of efficacy and safety outcomes for review of RSV vaccines for older adults
- Presentation from GSK on safety and efficacy of adjuvanted RSVpreF3 vaccine in adults 60 years and older
- Presentation from Pfizer on safety and efficacy of bivalent RSVpreF vaccine in adults 60 years and older

Recent Work Group Discussion

- Potential barriers to uptake of a novel RSV vaccine for older adults
 - Lack of patient and provider awareness of RSV as an important pathogen in older adults
 - Vaccine fatigue following multiple COVID-19 boosters
 - Increasing complexity of the adult immunization schedule
 - Hesitancy to co-administer RSV vaccine with other indicated vaccines

Agenda: Thursday October 20, 2022

- Safety and efficacy of RSVpreF3 Dr. Bishoy Rizkalla (GSK)
- Safety and efficacy of RSVpreF Dr. Alejandra Gurtman (Pfizer)
- Work group considerations Dr. Michael Melgar (CDC)

For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

